Kris MG - Search Results

1

Clinical Experience of Cerebrospinal Fluid-Based Liquid Biopsy Demonstrates Superiority of Cell-Free DNA over Cell Pellet Genomic DNA for Molecular Profiling.

Bale TA, Yang SR, Solomon JP, Nafa K, Middha S, Casanova J, Sadowska J, Skakodub A, Ahmad H, Yu HA, Riely GJ, Kris MG, Chandarlapaty S, Rosenblum MK, Gavrilovic I, Karajannis MA, Pentsova E, Miller A, Boire A, Mellinghoff I, Berger MF, Zehir A, Ladanyi M, Benayed R, Arcila ME. Bale TA, et al. Among authors: kris mg. J Mol Diagn. 2021 Jun;23(6):742-752. doi: 10.1016/j.jmoldx.2021.03.001. Epub 2021 Mar 27. J Mol Diagn. 2021. PMID: 33781965 Free PMC article.

2

KRAS mutations and primary resistance of lung adenocarcinomas to gefitinib or erlotinib.

Pao W, Wang TY, Riely GJ, Miller VA, Pan Q, Ladanyi M, Zakowski MF, Heelan RT, Kris MG, Varmus HE. Pao W, et al. Among authors: kris mg. PLoS Med. 2005 Jan;2(1):e17. doi: 10.1371/journal.pmed.0020017. Epub 2005 Jan 25. PLoS Med. 2005. PMID: 15696205 Free PMC article.

3

Clinical course of patients with non-small cell lung cancer and epidermal growth factor receptor exon 19 and exon 21 mutations treated with gefitinib or erlotinib.

Riely GJ, Pao W, Pham D, Li AR, Rizvi N, Venkatraman ES, Zakowski MF, Kris MG, Ladanyi M, Miller VA. Riely GJ, et al. Among authors: kris mg. Clin Cancer Res. 2006 Feb 1;12(3 Pt 1):839-44. doi: 10.1158/1078-0432.CCR-05-1846. Clin Cancer Res. 2006. PMID: 16467097 Clinical Trial.

4

Use of cigarette-smoking history to estimate the likelihood of mutations in epidermal growth factor receptor gene exons 19 and 21 in lung adenocarcinomas.

Pham D, Kris MG, Riely GJ, Sarkaria IS, McDonough T, Chuai S, Venkatraman ES, Miller VA, Ladanyi M, Pao W, Wilson RK, Singh B, Rusch VW. Pham D, et al. Among authors: kris mg. J Clin Oncol. 2006 Apr 10;24(11):1700-4. doi: 10.1200/JCO.2005.04.3224. Epub 2006 Feb 27. J Clin Oncol. 2006. PMID: 16505411

5

Novel D761Y and common secondary T790M mutations in epidermal growth factor receptor-mutant lung adenocarcinomas with acquired resistance to kinase inhibitors.

Balak MN, Gong Y, Riely GJ, Somwar R, Li AR, Zakowski MF, Chiang A, Yang G, Ouerfelli O, Kris MG, Ladanyi M, Miller VA, Pao W. Balak MN, et al. Among authors: kris mg. Clin Cancer Res. 2006 Nov 1;12(21):6494-501. doi: 10.1158/1078-0432.CCR-06-1570. Clin Cancer Res. 2006. PMID: 17085664

6

Prognostic and therapeutic implications of EGFR and KRAS mutations in resected lung adenocarcinoma.

Marks JL, Broderick S, Zhou Q, Chitale D, Li AR, Zakowski MF, Kris MG, Rusch VW, Azzoli CG, Seshan VE, Ladanyi M, Pao W. Marks JL, et al. Among authors: kris mg. J Thorac Oncol. 2008 Feb;3(2):111-6. doi: 10.1097/JTO.0b013e318160c607. J Thorac Oncol. 2008. PMID: 18303429 Free article.

7

Molecular characteristics of bronchioloalveolar carcinoma and adenocarcinoma, bronchioloalveolar carcinoma subtype, predict response to erlotinib.

Miller VA, Riely GJ, Zakowski MF, Li AR, Patel JD, Heelan RT, Kris MG, Sandler AB, Carbone DP, Tsao A, Herbst RS, Heller G, Ladanyi M, Pao W, Johnson DH. Miller VA, et al. Among authors: kris mg. J Clin Oncol. 2008 Mar 20;26(9):1472-8. doi: 10.1200/JCO.2007.13.0062. J Clin Oncol. 2008. PMID: 18349398 Clinical Trial.

8

EGFR mutations in lung adenocarcinomas: clinical testing experience and relationship to EGFR gene copy number and immunohistochemical expression.

Li AR, Chitale D, Riely GJ, Pao W, Miller VA, Zakowski MF, Rusch V, Kris MG, Ladanyi M. Li AR, et al. Among authors: kris mg. J Mol Diagn. 2008 May;10(3):242-8. doi: 10.2353/jmoldx.2008.070178. Epub 2008 Apr 10. J Mol Diagn. 2008. PMID: 18403609 Free PMC article.

9

Frequency and distinctive spectrum of KRAS mutations in never smokers with lung adenocarcinoma.

Riely GJ, Kris MG, Rosenbaum D, Marks J, Li A, Chitale DA, Nafa K, Riedel ER, Hsu M, Pao W, Miller VA, Ladanyi M. Riely GJ, et al. Among authors: kris mg. Clin Cancer Res. 2008 Sep 15;14(18):5731-4. doi: 10.1158/1078-0432.CCR-08-0646. Clin Cancer Res. 2008. PMID: 18794081 Free PMC article.

10

Morphologic features of adenocarcinoma of the lung predictive of response to the epidermal growth factor receptor kinase inhibitors erlotinib and gefitinib.

Zakowski MF, Hussain S, Pao W, Ladanyi M, Ginsberg MS, Heelan R, Miller VA, Rusch VW, Kris MG. Zakowski MF, et al. Among authors: kris mg. Arch Pathol Lab Med. 2009 Mar;133(3):470-7. doi: 10.5858/133.3.470. Arch Pathol Lab Med. 2009. PMID: 19260752 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

519 results

Search Page